RedHill Biopharma (RDHL) Posts Q3 Loss of 7c/Share

RedHill Biopharma (NASDAQ: RDHL) reported Q3 EPS of ($0.07), $0.51 better than the analyst estimate of ($0.58).

For earnings history and earnings-related data on RedHill Biopharma (RDHL) click here.

You May Also Be Interested In

• Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
• CMS targets 15% Medicare lab fee cuts, putting DGX and LH revenue at risk
• Credo Technology shares rise on analyst support and conference comments